dinaciclib

Dinaciclib is a potent, selective small molecule inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK1, CDK2, CDK5, and CDK9. By inhibiting these kinases in an ATP-competitive manner, dinaciclib disrupts cell cycle progression at the G1-S and G2-M transitions, leading to cell cycle arrest and apoptosis in tumor cells. It has demonstrated antineoplastic activity in preclinical models and clinical trials for various cancers including chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), and solid tumors. Dinaciclib was developed by Merck & Co., received orphan drug status from the FDA in 2011, and is administered intravenously[1][2][3][4][5].

Other names

dinaciclibSCH 727965SCH727965SCH-727965